Ergoteles’s Korro Bio KRRO Stock Holding History

Ergoteles’s Portfolio KRRO Stock Details KRRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-511	Closed	-$98.4K	–	1517
2022 Q4	$98.4K	Sell	511 -1,844	-78%	-$190K	﹤0.01%	1225
2022 Q3	$211K	Sell	2,355 -771	-25%	-$78.3K	0.01%	1147
2022 Q2	$234K	Buy	+3,126	New	+$211K	0.01%	1240

Other funds holding KRRO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

WPW

Waldron Private Wealth Bridgeville, Pennsylvania $2.56B AUM 17.72% 1-Year Est. Return

Ergoteles's KRRO Position: Q1 2023 in Review

Ergoteles sold out of Korro Bio (KRRO) in Q1 2023, closing a stake of 511 shares — an estimated $98.4K sold.

Ergoteles first reported a position in KRRO in Q2 2022 and held it in 3 quarters. The position peaked at $234K in Q2 2022. 43 funds tracked by Wall St. Rank hold KRRO as of Q1 2023.

Ergoteles reported no remaining Korro Bio position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 511 Korro Bio shares in Q1 2023, an estimated $98.4K.
Ergoteles first reported a position in Korro Bio in Q2 2022 and held it in 3 quarters.
Ergoteles's Korro Bio position peaked at $234K in Q2 2022.
43 funds tracked by Wall St. Rank held Korro Bio as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.